Regeneron buying 23andMe
Digest more
Regeneron Pharmaceuticals is set to acquire substantially all assets of 23andMe for $256 million. The deal is expected to close in Q3 2025
Regeneron Pharmaceuticals said on Monday it will buy genetic testing firm 23andMe Holding for $256 million through a bankruptcy auction, and promised to prioritize the ethical use of customers' DNA data.
Regeneron has been busy, with two health tech deals announced this week: One is about genetic data and one about AI. Both of them are about developing and selling drugs, really.
Explore more